Respiratory failure & ventilation
Long-term outcomes of patients with COVID-19 treated with helmet noninvasive ventilation or usual respiratory support: follow-up study of the Helmet-COVID randomized clinical trial
Primary result · 180-day mortalityResult — go to the resultRisk difference - 1.5% 95% CI - 12.3, 9.3Authors' conclusion
Helmet noninvasive ventilation did not reduce 180-day mortality or improve HRQoL compared to usual respiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.
Study context
- Population
- Adults with acute hypoxemic respiratory failure due to COVID-19 pneumonia3 lost to follow-up
- Participants
- 320 adults
- Comparison
- Helmet NIV vs usual respiratory support
- Helmet NIVn = 159
- Usual respiratory supportn = 158reference
- Primary endpoint
- Mortality
- Follow-up
- 180 days
Methodological detailspre-planned follow-up study, multicentre
- Pre-planned follow-up study
- Multicentre
Primary result
180-day mortality
Risk difference
- 1.5%
95% CI - 12.3, 9.3
P = 0.78
Events by treatment group
As reported in the abstract
Further findings
Median
| Outcome | Helmet NIV | Usual respiratory support | Median difference (95% CI) | P value |
|---|---|---|---|---|
| EQ-5D-5L index values (non-survivors assigned 0) · 180 daysModified intention-to-treat | 0.68 (IQR 0.00–1.00) | 0.67 (IQR 0.00–1.00) | 0.00 (- 0.32, 0.32) | P = 0.91 |
| EQ-VAS scores (non-survivors assigned 0) · 180 daysModified intention-to-treat | 70 (IQR 0–93) | 70 (IQR 0–90) | 0.00 (- 31.92, 31.92) | P = 0.55 |
Original publication
Long-term outcomes of patients with COVID-19 treated with helmet noninvasive ventilation or usual respiratory support: follow-up study of the Helmet-COVID randomized clinical trial. Intensive Care Med. Published 23 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →